AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01479660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic Capsules (450 billion CFU) will be orally administered daily for a period of 12 weeks and Probiotic in higher dose of (3600 billion CFU) will be administered daily for a period of 12 weeks
Study NCT02977624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Cognitive Orientation to daily Occupational Performance
Study NCT03711981 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP Block
Study NCT00869232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: 1.0mg/m2 days 1, 5, 8, \& 11
Study NCT01482871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-1001
Description: 2.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
Study NCT01482871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-1001
Description: 5.0 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
Study NCT00869232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 10 mg/m2 day 3
Study NCT00869232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 200 mg days 5-8
Study NCT00869232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg day 5-8
Study NCT00869232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 10 mg/m2 day 5-8
Study NCT00869232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: 10 mg/m2 day 5-8
Study NCT00869232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 400 mg/m2 day 5-8
Study NCT00869232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 40 mg/m2 day 5-8
Study NCT02244944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EZ-Urso combination therapy
Description: Ursodiol 13-15 mg per kg per day combined with Ezetimibe (Zetia) 10 mg per day
Study NCT01509573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Strengthening Intervention in Rwanda (FSI-R)
Description: Core components of the FSI-R are derived from the FBPI theoretical framework, and were chosen to address key risk factors identified in qualitative data. The FSI-R holds separate preliminary meetings with caregivers and children to prepare for a larger family meeting. In these modules, the interventionist helps caregivers and children prioritize concerns or key messages that they most want to share with the other party. Role play and discussions are used to impart improved parenting and communication skills. In the family meetings, children and caregivers share their concerns with one another and develop a shared family narrative, which integrates past events into a singular story with shared goals and a future orientation. These family modules also discuss the services and supports (formal and non-formal resources) that the family can engage with in order to achieve their shared goals.~8-12 weeks for 1-2 hours per week, depending on each family's pace and coverage of the material.
Study NCT02156674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naglazyme®
Description: 1 mg per kg of body weight administered once weekly as an intravenous infusion
Study NCT01192906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral doses, once a day for 52 weeks
Study NCT01192906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bitopertin [RO4917838]
Description: Oral dose level 1, once a day for 52 weeks
Study NCT01491490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GWP42003 : GWP42004 (40:1)
Description: Capsules taken once a day for 6 weeks
Study NCT01491490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules taken once a day for 6 weeks
Study NCT01192906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bitopertin [RO4917838]
Description: Oral dose level 2, once a day for 52 weeks
Study NCT01281358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HOP-ON
Description: A programme of activities which promote motor development
Study NCT01281358 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMILES
Description: Details are provided on ways for parents to interact with their premature infants
Study NCT00352365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally
Study NCT04320160 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich plasma
Description: Eight milliliters of blood sample will be aspirated from the patient's peripheral vein, and the sample will be centrifuged at 1,500 rpm for 5 minutes.~A 30-G needle will be used for superficial intradermal (ID) microinjections (0.1 mL per injection and space about 1 cm apart)
Study NCT04320160 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional CO2 laser
Description: Fifteen lesions will be treated by Fr: CO2 laser (10,600 nm; KES Corporation, Beijing, China).~Scanner spot size will be adjusted based on the lesion size. Density selected will be 0.6 in the static mode.~Two passes with minimal overlap will be delivered. The laser will be applied to the vitiligo lesion and over a thin rim of healthy skin
Study NCT03999606 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music Training - Choir participation
Description: Sixty participants, ages 50-65, will be recruited to partake in this study and will be randomly assigned to two groups:~participants in the experimental group will join a weekly on-line choir via Zoom, for ten weeks, directed by a professionally trained conductor from USC Department of Choral Music. The group practice will be accompanied by individual singing lessons (online or CDs) for home practice. Participants in the control group will be provided with weekly remote mindfulness lessons also on an online platform.
Study NCT03999606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Training - Choir participation
Description: Sixty participants, ages 50-65, will be recruited to partake in this study and will be randomly assigned to two groups:~participants in the experimental group will join a weekly on-line choir via Zoom, for ten weeks, directed by a professionally trained conductor from USC Department of Choral Music. The group practice will be accompanied by individual singing lessons (online or CDs) for home practice. Participants in the control group will be provided with weekly remote mindfulness lessons also on an online platform.
Study NCT03542318 — intervention group
Intervention type: OTHER
Intervention: Pulmonary Rehabilitation
Description: A multidisciplinary PR programme was delivered twice weekly for 12 weeks. Each class was of 2 hours in duration. The first hour had an exercise component. Inspiratory muscle training was carried out using the Respironics IMT Threshold trainer® during the class. Educational sessions covered various aspects of pulmonary fibrosis care and self-management delivered. Patients also received an individualized home exercise programme consisting of exercise similar to what was being carried out during the classes. Each participant was encouraged to perform at least 20 minutes of these exercises per day.
Study NCT02778763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBLB612
Description: 4 μg CBLB612 SQ
Study NCT02778763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02905240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nSTRIDE APS
Description: single intra-articular injection
Study NCT02778763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01140984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (Intra-arterial continuous infusion of corticosteroids)
Description: Sedation/anesthesia of patient followed by placement of a 4F vascular sheath and a diagnostic and hepatic angiogram. Angiographic catheter tip to be placed in the proximal proper hepatic artery, secured in place externally and connected to an arterial line pressurized system which allows continuous drip infusion of methylprednisolone diluted in normal saline (600mg/m2 with maximal total dose of 100mg diluted in 480cc in normal saline administered at 20cc/hr for 24 hours).
Study NCT04006847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic Acid
Description: Eicosapentaenoic Acid once per day orally
Study NCT04006847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor
Description: Tyrosine kinase inhibitor to be administered at subjects' pre-study dose
Study NCT02087579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole, oral formulation
Description: Aripiprazole tablets will be administered orally (by mouth), at no dose restriction, as per the locally approved label indications.
Study NCT02087579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine, oral formulation
Description: Olanzapine tablets will be administered orally, at no dose restriction as per the locally approved label indications.
Study NCT02087579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone, oral formulation
Description: Paliperidone prolonged-release/extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
Study NCT02087579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone, LAI
Description: Paliperidone long-acting injectable (LAI) i.e., paliperidone palmitate injections, will be administered per the locally approved label indications.
Study NCT02087579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine, oral formulation
Description: Quetiapine immediate-release (IR) formulation or extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
Study NCT02087579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone, oral formulation
Description: Risperidone tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
Study NCT02087579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone, LAI
Description: Risperidone LAI injections will be administered will be administered per the locally approved label indications.
Study NCT00066807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: Planned duration of chemotherapy: 2 months if an anthracycline is included (e.g., 4 cycles of EC or AC) or 4 months if no anthracycline is given (e.g., 6 cycles of CMF) is recommended. Unless medically contraindicated, an anthracycline-containing regimen using epirubicin should be given.
Study NCT00066807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Exemestane 25 mg orally daily for until 5 years from date of randomization, unless relapse or intolerance should occur earlier.
Study NCT00066807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen
Description: Tamoxifen 20 mg orally daily until 5 years from date of randomization, unless relapse or intolerance should occur earlier.
Study NCT00066807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin
Description: Triptorelin (GnRH analogue) 3.75 mg by intramuscular injection every 28 days for 5 years from randomization, unless relapse or intolerance should occur earlier or surgical oophorectomy or ovarian irradiation is subsequently performed.
Study NCT00066807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oophorectomy
Description: Bilateral surgical oophorectomy via laparotomy or laparoscopy.
Study NCT00066807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ovarian irradiation
Description: Bilateral ovarian irradiation.
Study NCT03250910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir and Velpatasvir
Description: All patients received a generic version of VEL/SOF fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.
Study NCT03250910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Velpatasvir
Description: All patients received a generic version of VEL/SOF fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.
Study NCT03250910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Patients with decompensated cirrhosis (Child-Pugh B or C), received weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight \< 75 mg) for 12 weeks.
Study NCT03250910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Patients with decompensated cirrhosis (Child-Pugh B or C), received weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight \< 75 mg) for 12 weeks.
Study NCT01352559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: responders
Description: Antidepressants administration for 6 weeks under therapeutic dose
Study NCT01352559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-responders
Description: Antidepressants administration for 6 weeks under therapeutic dose
Study NCT01347398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PSG
Description: Sleep study made by PSG (polysomnography)
Study NCT01347398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MicroMESAM system
Description: Sleep study made by MicroMESAM system
Study NCT03038178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAI plus multi-drug regimen
Description: Liposomal Amikacin for Inhalation (LAI) is the experimental treatment which, in this single arm will be taken in conjunction with standard of care multi-drug treatment regimen
Study NCT01645228 — intervention group
Intervention type: RADIATION
Intervention: coronary calcium score measurement
Study NCT01645228 — intervention group
Intervention type: BIOLOGICAL
Intervention: high sensitivity C reactive protein measurement
Study NCT01645228 — intervention group
Intervention type: PROCEDURE
Intervention: ankle brachial index measurement
Study NCT01015911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-75
Description: SGN-75 (IV) in 21- or 28-day cycles; dose range: 0.3-9 mg/kg
Study NCT01081483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-072
Description: See arm description for more information
Study NCT01081483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See arm description for more information
Study NCT03727464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstract priming
Description: Patients were primed with a list of abstract during their general anesthesia
Study NCT03727464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concrete priming
Description: Patients were primed with a list of concrete during their general anesthesia
Study NCT03727464 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Controls
Description: Patients did not receive any specific stimulation with words during their general anesthesia
Study NCT03727464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol general anesthesia
Study NCT03727464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol general anesthesia
Study NCT03727464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane general anesthesia
Study NCT03727464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane general anesthesia
Study NCT02869295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: Participants in the dose escalation cohorts will be treated every 21 days (q21d) or every 14 days (q14d) until tumor progression.
Study NCT02982447 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: blue laser imaging colonoscopy
Description: Insertion to cecum was performed under white light(WL) and once the cecum was reached, the Blue Laser Imaging mode was switched on during withdrawal of endoscope for complete colonic examination. Second colonoscopic examination was performed in a similar manner after the first complete withdrawal of the colonoscope. WL was used on insertion and WL was used on withdrawal
Study NCT02982447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional white light colonoscopy
Description: In this arm, WL was used for both insertion and withdrawal of the colonoscope during the first-pass and second-pass examinations.
Study NCT05466513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial tactile stimulation
Description: Tactile stimulation was given around the face with soft tissue paper for two minutes.
Study NCT03770000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenalisib
Description: Tenalisib, BID orally daily
Study NCT02646423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prior CD Decision App
Description: The Prior CD Decision App begins with an explanation that its goal is to help the user better understand the two approaches to delivery she is eligible for (trial of labor after cesarean (TOLAC) and elective repeat cesarean delivery (ERCD)), and that its goal is to help her engage with her provide in making an informed, shared decision regarding which approach to undergo. It includes four sections: a calculator to estimate the likelihood of having a vaginal delivery if she undergoes TOLAC, a series of information pages that include graphical presentations of the chances of various potential outcomes of the two options, a series of values clarification exercises to help the user think through what's important to her, and a summary print out for her to keep.
Study NCT03770000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Romidepsin IV
Study NCT02751632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support and Problem Solving Therapy
Description: Support and Problem Solving Therapy involves providing participants with emotional support and helping them to resolve their problems in day-to-day life.
Study NCT02751632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Case Management
Description: CBCM has a number of different elements including: strategies to help with stress management; therapy that targets thinking and behavioural patterns; practical assistance, as well as yoga and mindfulness.
Study NCT03425149 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA1601
Description: purified inactivated ZIKV vaccine candidate adsorbed on alum
Study NCT03425149 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate buffered saline (PBS)
Study NCT01482871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-1001
Description: 7.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
Study NCT01461343 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CT imaging, functional PET imaging
Description: Physiology study using CT and functional PET imaging with 13NN and 11CO as radiotracers; images obtained before and after administration of inhaled nitric oxide and balance 80% oxygen as pulmonary vasodilators
Study NCT02751632 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioural Case Management
Description: CBCM has a number of different elements including: strategies to help with stress management; therapy that targets thinking and behavioural patterns; practical assistance, as well as yoga and mindfulness.
Study NCT02751632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Participants will commence on 1 capsule of fluoxetine 20 mg, to be taken in the morning. The medication can be increased to fluoxetine 40 mg daily if there has been a poor clinical response after the first 6 weeks of treatment.
Study NCT02751632 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will commence on 1 capsule of the placebo pill, to be taken in the morning. The medication can be increased to 2 placebo capsules if there has been a poor clinical response after the first 6 weeks of treatment.
Study NCT02751632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3-monthly monitoring
Description: Study participants will be contacted on a 3-monthly basis by a study clinician who will be assessing the participant's risk.
Study NCT03108391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu AuraGain
Study NCT03108391 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Supreme